Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19

[1]  D. Osoba,et al.  Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. , 2005, European journal of cancer.

[2]  D. Ghersi,et al.  Single agent versus combination chemotherapy for metastatic breast cancer. , 2005, The Cochrane database of systematic reviews.

[3]  K. Gelmon,et al.  Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Fairclough.  Design and analysis of quality of life studies in clinical trials , 2002, Quality of Life Research.

[5]  D. Osoba,et al.  Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Molenberghs,et al.  Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study. , 2000, European journal of cancer.

[7]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Lee-Jen Wei,et al.  Combining dependent tests with incomplete repeated measurements , 1985 .

[9]  John M. Lachin,et al.  Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations , 1984 .